3619 Liraglutide in Islet Cell Transplants with Type I Diabetes

• Research type

  Research Study

• Full title

  A 52-week Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre, Multinational Exploratory Trial in Islet Cell Transplant Subjects with Type 1 Diabetes Mellitus to Evaluate the Early Use of Liraglutide As An Adjunct to Standard Care Regarding the Percentage of Subjects Achieving Insulin Independence After First Transplantation.

• IRAS ID

  98959

• Contact name

  Paul Johnson

• Sponsor organisation

  Novo Nordisk

• Eudract number

  2009-013090-18

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  The main purpose of this study is to investigate if treatment with Liraglutide can increase the proportion of subjects with Type 1 Diabetes who are insulin-dependent at one year after a single donor islet cell transplant.

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  12/SC/0160

• Date of REC Opinion

  7 Jun 2012

• REC opinion

  Further Information Favourable Opinion